Verge Genomics is a next-generation biopharmaceutical start-up using human genomics to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient tissue profiling, human genetics, and machine learning to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development.